PCI Biotech to present at TIDES USA 2022
May 09, 2022 02:45 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 9 May 2022 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced a...
PCI Biotech: Invitation to Q1 2022 results presentation
May 04, 2022 09:10 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 4 May 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q1 2022 interim report on Wednesday 11 May 2022, 08:30am – 09:30am CEST (local time). The...
Notice of Annual General Meeting 2022
May 04, 2022 05:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway 4 May 2022 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 25 May 2022 at 10:00am (CEST). The...
PCI Biotech Holding ASA publishes the Annual Report 2021
April 28, 2022 04:59 ET
|
PCI Biotech Holding ASA
Oslo, Norway, April 28, 2022The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2021 and the report is attached, in addition to the report according to the European Single...
PCI Biotech: CEO resigns to assume new position
March 28, 2022 08:21 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 28 March 2022 – PCI Biotech (OSE: PCIB) announces today that CEO, Dr Per Walday has resigned to assume a new position. Dr Walday has a notice period of six months, and he will step down...
PCI Biotech fourth quarter and preliminary full year 2021 results
February 18, 2022 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 18 February 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full-year 2021 results. Please find enclosed the...
PCI Biotech: Invitation to Q4 2021 result presentation
February 14, 2022 06:50 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 14 February 2022 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q4 and preliminary full-year 2021 results on Friday 18 February 2022 at Oslo Cancer Cluster...
PCI Biotech: Update on the RELEASE trial
January 24, 2022 15:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 24 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has decided to stop the RELEASE study and focus their drug...
PCI Biotech: Publication of preclinical tuberculosis results
January 11, 2022 03:01 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 11 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that results from preclinical studies on tuberculosis performed in collaboration...
PCI Biotech and MDimune announce research collaboration agreement
January 05, 2022 01:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company...